A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

被引：1
|
作者：
Daver, Naval [1 ]
Dao, Kim-Hien [2 ]
Assad, Albert [3 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Incyte Corp, Wilmington, DE USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-028
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [41] Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Ohanian, Maro N.
    Zhou, Lingsha
    Pierce, Sherry A.
    Gergis, Romany
    Borthakur, Gautam
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Daver, Naval G.
    BLOOD, 2018, 132
  • [42] Updated Results of a Phase 2 Study of Ruxolitinib in Combination With 5-Azacitidine in Patients With Myelofibrosis
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 12 - 13
  • [43] Ongoing phase 1/2 study of INCB050465 for relapsed/refractory (R/R) B-cell malignancies (CITADEL-101).
    Ramchandren, Rod
    Phillips, Tycel Jovelle
    Wertheim, Michael
    Gutierrez, Martin
    Edenfield, William Jeffery
    Akard, Luke Paul
    Caimi, Paolo Fabrizio
    Call, Justin
    Persky, Daniel Oscar
    DeMarini, Douglas James
    Zhou, Li
    Yeleswaram, Swamy
    Forero-Torres, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
    Bose, Prithviraj
    Swaminathan, Mahesh
    Pemmaraju, Naveen
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval G.
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Schroeder, Kurt D.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1767 - 1774
  • [45] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
    Mascarenhas, John
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Jegg, Anna Maria
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
  • [46] EFFICACY AND SAFETY OF RUXOLITINIB IN ELDERLY PATIENTS WITH MYELOFIBROSIS: A MULTICENTER SURVEY
    Palandri, F.
    Benevolo, G.
    Palumbo, G. A.
    Bonifacio, M.
    Di Veroli, A.
    Polverelli, N.
    Andriani, A.
    Tieghi, A.
    Tiribelli, M.
    Binotto, G.
    Martino, B.
    Petriccione, L.
    D'Adda, M.
    Crugnola, M.
    Cavazzini, F.
    Bergamaschi, M.
    Isidori, A.
    Trawinska, M.
    Ibatici, A.
    Bosi, C.
    Sgherza, N.
    Montanaro, M.
    Breccia, M.
    Sabattini, E.
    Catani, L.
    Vitolo, U.
    Merli, F.
    Aversa, F.
    Vallisa, D.
    Russo, D.
    Semenzato, P.
    Visani, G.
    Fanin, R.
    Cuneo, A.
    Cavo, M.
    Vianelli, N.
    Latagliata, R.
    HAEMATOLOGICA, 2017, 102 : 93 - 94
  • [47] Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
    Verstovsek, Srdan
    Foltz, Lynda
    Gupta, Vikas
    Hasserjian, Robert
    Manshouri, Taghi
    Mascarenhas, John
    Mesa, Ruben
    Pozdnyakova, Olga
    Ritchie, Ellen
    Veletic, Ivo
    Gamel, Katia
    Hamidi, Habib
    Han, Lyrialle
    Higgins, Brian
    Trunzer, Kerstin
    Uguen, Marianne
    Wang, Dao
    El-Galaly, Tarec Christoffer
    Todorov, Boyan
    Gotlib, Jason
    HAEMATOLOGICA, 2023, 108 (10) : 2730 - 2742
  • [48] An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies
    Phillips, Tycel
    Ramchandren, Rod
    Wertheim, Michael S.
    Gutierrez, Martin E.
    Edenfield, William J.
    Dawkins, Fitzroy
    DeMarini, Doug J.
    Zhou, Li
    Yeleswaram, Swamy
    Newton, Robert C.
    Chen, Xuejun
    Forero-Torres, Andres
    BLOOD, 2016, 128 (22)
  • [49] Results From a Phase 1/2 Study of INCB050465, a Potent and Highly Selective PI3K delta Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies
    Martin, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 9 - 10
  • [50] Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
    Sorensen, Anders Lindholm
    Mikkelsen, Stine Ulrik
    Knudsen, Trine Alma
    Bjorn, Mads Emil
    Andersen, Christen Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    Patel, Dustin Andersen
    Gjerdrum, Lise Mette Rahbek
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Ellervik, Christina
    Pallisgaard, Niels
    Thomassen, Mads
    Kjaer, Lasse
    Skov, Vibe
    Hasselbach, Hans Carl
    HAEMATOLOGICA, 2020, 105 (09) : 2262 - 2272
12345